We are headquartered at One Letterman Drive, Building A, Suite A4-300, San Francisco, CA 94129.
Braveheart Bio was incorporated in May 2024 in the State of Delaware and began operations in 2025.
Braveheart Bio's auditor is Ernst & Young LLP.
Braveheart Bio's corporate counsel is Goodwin Procter LLP.
You can reach the Braveheart Bio Investor Relations team via e-mail at ir@braveheart.bio.
If you are a registered Braveheart Bio shareholder, please contact our transfer agent:
Computershare
Website: www-us.computershare.com/Investor
Tel: 1 (800) 736-3001
Online Inquiries: www-us.computershare.com/investor/Contact
Written requests:
Computershare
150 Royall St
Suite 101
Canton MA 02021
You can visit braveheart.bio and ir.braveheart.bio for more information.
You can find news releases in the News & Events section and financial reports in the Financials & Filings section within this investor relations website.
SEC documents are available on the SEC Filings section of this investor relations website.
August 6th, 2026
NASDAQ: BRVE
December 31st
10567X 101
No